Post‐hoc analysis in Alzheimer's study shows benefit of LMTM monotherapy

A randomized, double‐blind, parallel‐group study of a tau protein aggregation inhibitor, while not showing treatment benefit in the primary analysis of its effect on slowing disease progression in Alzheimer's disease patients, found significant results in a post‐hoc analysis for patients receiving the drug as monotherapy. Patients receiving leuco‐methylthioninium bis[hydromethanesulfonate] (LMTM) monotherapy at doses of either 75 or 125 mg twice a day saw benefits in both cognition and activities of daily living, researchers reported. Study results were published online Nov. 15, 2016, in The Lancet .